Entries by oncotron

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the close of its successful £40.5 million Series A financing. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and co-lead from the seed round, Epidarex Capital.

Senior Scientist – Microfluidics

We are seeking an outstanding scientist with experience in microfluidics to join Curve Therapeutics, an innovative, venture-backed start-up company based in Southampton, UK. The successful applicant will become part of a multidisciplinary team that is developing our proprietary high-throughput microfluidics screening platform.

Read more

Curve Therapeutics appoints Dr Sally Price as Vice President of Biology

Dr Price brings over 20 years of experience in drug discovery and development, across pharma and biotech Southampton, UK, 18 September 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a game-changing, functional drug discovery platform, today announces the appointment of Dr Sally Price as its Vice President of Biology. Dr […]

Curve Therapeutics Expands Leadership Team and Scientific Advisory Board: Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets

Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets Julian Downward (Francis Crick Institute) and Prof. Steven Benkovic (Penn State University) join the Scientific Advisory Board Relocation to bespoke laboratories and offices at Southampton Science Park Southampton, UK, 2 May 2023 – Curve Therapeutics (Curve), a […]

Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform

Curve’s innovative mammalian cell drug discovery platform to enable identification and optimisation of novel small molecule drug candidates against MSD targets Potentially game-changing platform enables direct discovery of functionally active molecules against difficult to drug targets expressed in their native intracellular environment Southampton, UK, 16th February 2022: Curve Therapeutics (Curve), a private biotechnology company pioneering […]